REG-Bioventix Plc: Trading Update, Notice of Results & AGM <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

04/09/2017 07:00

Bioventix plc

(“Bioventix” or the “Company”)

Trading Update, Notice of Results and AGM

Trading Update

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for application in
clinical diagnostics, announces a trading update.

The Board is pleased to report that revenues for the financial year ended 30
June 2017 are expected to be marginally in excess of £7M (2015/16: £5.5M).
Since the cost-base of the Company continues to follow a similar shallow
trajectory as in previous years, both revenues and profits before tax are
expected to be ahead of market expectations for the year ended 30 June 2017.

Notice of Results

The audited accounts for the year ended 30 June 2017 are due to be released on
Monday 17 October 2017. We will comment on the revenues in more detail at this
time. 

AGM

The Bioventix AGM will be held at 2pm on Thursday 14(th) December at Farnham
Castle (GU9 0AG)

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.

For further information please contact:

 Bioventix plc Peter Harrison                         Chief Executive Officer              Tel: 01252 728 001  
                                                                                                               
 finnCap Ltd Geoff Nash/Simon Hicks Stephen Norcross  Corporate Finance Corporate Broking  Tel: 020 7220 0500  

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2017 PR Newswire Association,LLC. All Rights Reserved